Thrombosis in Systemic Lupus Erythematosus

Anita Palatinus; Murray Adams

doi:10.1055/s-0029-1242716

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2009; 35(7): 621-629
DOI: 10.1055/s-0029-1242716

Thrombosis in Systemic Lupus Erythematosus

Anita Palatinus¹ , Murray Adams¹

¹School of Human Life Sciences, University of Tasmania, Tasmania, Australia

Abstract

ABSTRACT

Systemic lupus erythematosus (SLE) is a potentially fatal multiorgan inflammatory disease that primarily affects females. Due to the heterogeneity of clinical manifestations and lack of laboratory tests that are both specific and sensitive for the disease, diagnosis of SLE can often be difficult. Although the precise etiology remains to be fully elucidated, it is probable that various environmental, genetic, and hormonal factors contribute to the development of the disease. Patients with SLE have an increased risk for premature thrombosis and/or atherosclerosis, with up to half experiencing a thrombotic event. Furthermore, antiphospholipid antibodies probably play a key role in the development of thrombosis by affecting various hemostatic protein interactions with phospholipids and cell surfaces as well as platelet function. Despite recent advances in knowledge related to the factors that contribute to the pathophysiology of SLE, numerous challenges related to earlier diagnosis as well as the prediction and prevention of thrombotic events remain to be fully addressed.

KEYWORDS

Systemic lupus erythematosus - lupus - thrombosis - antiphospholipid antibody

Volltext

Referenzen

REFERENCES

1 Swigris J J, Fischer A, Gillis J, Meehan R T, Brown K K. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008; 133(1) 271-280
2 Cervera R, Khamashta M A, Font J European Working Party on Systemic Lupus Erythematosus et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5) 299-308
3 Cervera R, Khamashta M A, Font J European Working Party on Systemic Lupus Erythematosus et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. Medicine (Baltimore). 1999; 78(3) 167-175
4 McClain M T, Arbuckle M R, Heinlen L D et al.. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004; 50(4) 1226-1232
5 Asherson R A. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost. 2008; 34(3) 227-235
6 Danchenko N, Satia J A, Anthony M S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006; 15(5) 308-318
7 D'Cruz D P. Systemic lupus erythematosus. BMJ. 2006; 332(7546) 890-894
8 Petri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008; 17(5) 412-415
9 Rahman A, Isenberg D. Systemic lupus erythematosus. N Engl J Med. 2008; 358 929-939
10 Mills J A. Systemic lupus erythematosus. N Engl J Med. 1994; 330(26) 1871-1879
11 Panjwani S. Early diagnosis and treatment of discoid lupus erythematosus. J Am Board Fam Med. 2009; 22(2) 206-213
12 van Vugt R M, Derksen R H, Kater L, Bijlsma J W. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis. 1998; 57(9) 540-544
13 Wang Z, Tang Z, Zhang H T, Hu W X, Liu Z H, Li L S. Clinicopathological characteristics of familial SLE patients with lupus nephritis. Lupus. 2009; 18(3) 243-248
14 Mosley K, Tam F W, Edwards R J, Crozier J, Pusey C D, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford). 2006; 45(12) 1497-1504
15 Cervera R, Font J, Paré C et al.. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis. 1992; 51(2) 156-159
16 Frostegård J. Systemic lupus erythematosus and cardiovascular disease. Lupus. 2008; 17(5) 364-367
17 Hahn B H. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003; 349(25) 2379-2380
18 Salmon J E, de Groot P G. Pathogenic role of antiphospholipid antibodies. Lupus. 2008; 17(5) 405-411
19 Kim S Y, Lee J H. Prognosis of neonates in pregnant women with systemic lupus erythematosus. Yonsei Med J. 2008; 49(4) 515-520
20 Yan Yuen S, Krizova A, Ouimet J M, Pope J E. Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review. Open Rheumatol J. 2008; 2 89-98
21 Doria A, Tincani A, Lockshin M. Challenges of lupus pregnancies. Rheumatology (Oxford). 2008; 47(Suppl 3) iii9-iii12
22 Ginsberg J S, Brill-Edwards P, Johnston M et al.. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood. 1992; 80(4) 975-980
23 Giannouli S, Voulgarelis M, Ziakas P D, Tzioufas A G. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. 2006; 65(2) 144-148
24 Voulgarelis M, Kokori S I, Ioannidis J P, Tzioufas A G, Kyriaki D, Moutsopoulos H M. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis. 2000; 59(3) 217-222
25 Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006; 45(7) 851-854
26 Criswell L A. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis. 2008; 66(3) 176-183
27 Cooper G S, Gilbert K M, Greidinger E L et al.. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Environ Health Perspect. 2008; 116(6) 695-702
28 Cross L S, Aslam A, Misbah S A. Antinuclear antibody-negative lupus as a distinct diagnostic entity—does it no longer exist?. QJM. 2004; 97(5) 303-308
29 Reichlin M. ANA negative systemic lupus erythematosus sera revisited serologically. Lupus. 2000; 9(2) 116-119
30 Witte T, Hartung K, Sachse C SLE Study Group et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int. 1998; 18(3) 85-91
31 Koffler D, Agnello V, Kimkel H G. Polynucleotide immune complexes in serum and glomeruli of patients with systemic lupus erythematosus. Am J Pathol. 1974; 74(1) 109-124
32 Tsao B P, Ebling F M, Roman C, Panosian-Sahakian N, Calame K, Hahn B H. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J Clin Invest. 1990; 85(2) 530-540
33 Satoh M, Kumar A, Kanwar Y S, Reeves W H. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A. 1995; 92(24) 10934-10938
34 Ruiz-Irastorza G, Egurbide M V, Martinez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus. 2004; 13(12) 900-905
35 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2) 295-306
36 Swadzba J, De Clerck L S, Stevens W J et al.. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol. 1997; 24(9) 1710-1715
37 Oosting J D, Derksen R H, Bobbink I W, Hackeng T M, Bouma B N, de Groot P G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood. 1993; 81(10) 2618-2625
38 Favaloro E J, Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost. 2008; 34(4) 389-410
39 Feinbloom D, Bauer K A. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005; 25(10) 2043-2053
40 Toloza S M, Uribe A G, McGwin Jr G LUMINA Study Group et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004; 50(12) 3947-3957
41 Manzi S, Meilahn E N, Rairie J E et al.. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145(5) 408-415
42 Ho K T, Ahn C W, Alarcón G S et al.. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford). 2005; 44(10) 1303-1307
43 Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990; 112(9) 682-698
44 Kaiser R, Cleveland C M, Criswell L A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009; 68(2) 238-241
45 Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost. 2003; 1(5) 931-942
46 Sallai K K, Nagy E, Bodó I, Mohl A, Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol. 2007; 36(3) 198-205
47 Kinev A V, Roubey R A. Tissue factor in the antiphospholipid syndrome. Lupus. 2008; 17(10) 952-958
48 Tektonidou M G, Laskari K, Panagiotakos D B, Moutsopoulos H M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009; 61(1) 29-36
49 Khamashta M A, Cuadrado M J, Mujic F, Taub N A, Hunt B J, Hughes G R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995; 332(15) 993-997
50 Rosove M H, Brewer P M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992; 117(4) 303-308
51 Anders H J. Predicting thrombosis in systemic lupus erythematosus. Nat Clin Pract Nephrol. 2009; 5(2) 68-69
52 Wu H, Birmingham D J, Rovin B et al.. D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol. 2008; 3(6) 1628-1636
53 Forastiero R R, Martinuzzo M E, de Larrañaga G F. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. 2005; 14(2) 129-136
54 Nemerson Y. Tissue factor and hemostasis. Blood. 1988; 71(1) 1-8
55 de Prost D, Ollivier V, Ternisien C, Chollet-Martin S. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb Haemost. 1990; 64(2) 216-221
56 Zhou H, Wolberg A S, Roubey R A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood. 2004; 104(8) 2353-2358
57 Martini F, Farsi A, Gori A M et al.. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus. 1996; 5(3) 206-211
58 Forastiero R R, Martinuzzo M E, Broze G J. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost. 2003; 1(4) 718-724
59 Adams M, Breckler L, Stevens P, Thom J, Baker R, Oostryck R. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. Haematologica. 2004; 89(8) 985-990
60 Lean S Y, Ellery P, Ivey L et al.. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation. Haematologica. 2006; 91(10) 1360-1366
61 Roubey R A. Mechanisms of autoantibody-mediated thrombosis. Lupus. 1998; 7(Suppl 2) S114-S119
62 Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood. 1998; 91(6) 1999-2004
63 Pierangeli S, Mariano E, Vega-Ostertag M et al.. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med. 2007; 9 1-15
64 Roubey R A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood. 1994; 84(9) 2854-2867
65 Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem. 2005; 51(3) 545-552
66 Ekdahl K N, Bengtsson A A, Andersson J et al.. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol. 2004; 125(1) 74-78
67 Lutters B C, Derksen R H, Tekelenburg W L, Lenting P J, Arnout J, de Groot P G. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem. 2003; 278(36) 33831-33838
68 Urbanus R T, Derksen R H, de Groot P G. Platelets and the antiphospholipid syndrome. Lupus. 2008; 17(10) 888-894
69 Dhar J P, Andersen J, Essenmacher L, Ager J, Bentley G, Sokol R J. Thrombophilic patterns of coagulation factors in lupus. Lupus. 2009; 18(5) 400-406
70 Pereira J, Alfaro G, Goycoolea M et al.. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost. 2006; 95(1) 94-99
71 Danese S, de la Motte C, Reyes B M, Sans M, Levine A D, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004; 172(4) 2011-2015
72 Joseph J E, Harrison P, Mackie I J, Isenberg D A, Machin S J. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol. 2001; 115(2) 451-459
73 Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies—co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost. 2004; 91(5) 967-976
74 Jankowski M, Vreys I, Wittevrongel C et al.. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003; 101(1) 157-162
75 Dorsch C, Meyerhoff J. Elevated plasma beta-thromboglobulin levels in systemic lupus erythematosus. Thromb Res. 1980; 20(5-6) 617-622
76 Ekdahl K N, Rönnblom L, Sturfelt G, Nilsson B. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis. Arthritis Rheum. 1997; 40(12) 2178-2186
77 Lockshin M D. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis. 2008; 66(3) 195-197
78 Afeltra A, Vadacca M, Conti L et al.. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheum. 2005; 53(3) 452-459
79 Lincz L F, Adams M J, Scorgie F E, Thom J, Baker R I, Seldon M. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagul Fibrinolysis. 2007; 18(6) 559-564
80 Tan E M, Cohen A S, Fries J F et al.. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11) 1271-1277
81 Gill J M, Quisel A M, Rocca P V, Walters D T. Diagnosis of systemic lupus erythematosus. Am Fam Physician. 2003; 68(11) 2179-2186
82 Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9) 1725
83 Fernando M M, Stevens C R, Sabeti P C et al.. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet. 2007; 3(11) e192
84 Graham R R, Ortmann W, Rodine P et al.. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet. 2007; 15(8) 823-830
85 Graham R R, Ortmann W A, Langefeld C D et al.. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am J Hum Genet. 2002; 71(3) 543-553
86 Walport M J. Complement and systemic lupus erythematosus. Arthritis Res. 2002; 4(Suppl 3) S279-S293
87 Prokunina L, Castillejo-López C, Oberg F et al.. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002; 32(4) 666-669
88 Chung S A, Criswell L A. PTPN22: its role in SLE and autoimmunity. Autoimmunity. 2007; 40(8) 582-590
89 Kyogoku C, Langefeld C D, Ortmann W A et al.. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004; 75(3) 504-507
90 Graham R R, Kozyrev S V, Baechler E C Argentine and Spanish Collaborative Groups et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006; 38(5) 550-555
91 Graham R R, Kyogoku C, Sigurdsson S et al.. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 2007; 104(16) 6758-6763
92 Sigurdsson S, Nordmark G, Göring H H et al.. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005; 76(3) 528-537
93 Karassa F B, Trikalinos T A, Ioannidis J P. FcgammaRIIa-SLE Meta-Analysis Investigators . Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002; 46(6) 1563-1571
94 Karassa F B, Trikalinos T A, Ioannidis J P. Fc gamma RIIIA-SLE meta-analysis investigators . The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int. 2003; 63(4) 1475-1482
95 Russell A I, Cunninghame Graham D S, Shepherd C et al.. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004; 13(1) 137-147
96 Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz H G, Möröy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet. 2000; 25(2) 177-181
97 Yasutomo K, Horiuchi T, Kagami S et al.. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001; 28(4) 313-314
98 Remmers E F, Plenge R M, Lee A T et al.. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007; 357(10) 977-986

Murray AdamsPh.D. M.A.I.M.S.

Senior Lecturer, School of Human Life Sciences

University of Tasmania, Tasmania, Australia

eMail: Murray.Adams@utas.edu.au